Latest news Latest news Latest news

Latest news

Corporate

Aankondiging door Gimv NV overeenkomstig artikel 7:189, lid 2 van het Wetboek van vennootschappen en verenigingen

15/01/2025 - 07:23

Corporate

Report of the Extraordinary General Shareholders’ Meeting

13/01/2025 - 17:45

Portfolio

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

10/01/2025 - 15:45

Portfolio

FIRE1 Secures $120 Million Financing to Revolutionize Heart Failure Care

07/01/2025 - 09:05

Corporate

Report of the Extraordinary General Shareholders’ Meeting

23/12/2024 - 17:45

Portfolio

B+N acquires KÖBERL Group, a leading provider of facility management and technical building services, from Gimv

18/12/2024 - 07:30

Portfolio

Belgian software company Itineris accelerates expansion in the U.S.

13/12/2024 - 09:35

Portfolio

Gimv acquires Groupe Tibbloc, leader in rental of ready-to-use temporary energy solutions and related services, from Ciclad

04/12/2024 - 07:30

Portfolio

Gimv invests in the further growth and internationalization of Lupine Lighting Systems

02/12/2024 - 07:30

Corporate

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

21/11/2024 - 06:58

Portfolio

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

20/11/2024 - 07:45

Portfolio

Gimv participates in a $92M Series A financing round at Kivu Bioscience to advance next-gen antibody-drug conjugates

28/10/2024 - 17:45

Contact information

Investor Relations Investor Relations Investor Relations

Investor Relations

Do you have any questions or require more information? Please contact us.